Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants.
Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.
Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66. The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.
March 31, 2008